This double-blind study included 21162 patients with a history of acute myocardial infarction randomized to ticagrelor 90 mg e/12 h, ticagrelor 60 mg e/12 h or placebo. All patients received aspirin and had additional risk factors such as age or diabetes. The history of infarction should be between one and three years before being included...
Low doses of aspirin for primary prevention in elderly patients with multiple risk factors.
Article The goal of this study was to assess the efficacy of low doses of aspirin (AAS) for primary prevention of cardiovascular events in Japanese elderly patients with multiple risk factors for arteriosclerosis but with no history of heart disease. This open study included patients between 60 and 85 with risk factors such as high...
FACTOR 64: Routine coronary CT angiography in patients at high risk for heart disease.
Article 900 patients with asymptomatic diabetes mellitus were randomized to CT angiography vs. Standard management. Primary end point was a combination of death, infarction and unstable angina. 63% of patients randomized to CT angiography presented some degree of heart disease and 4.7% presented severe lesions. This resulted in more coronary interventions, more use of statins...
GIPS -III: Metformin does not improve ejection fraction in non-diabetic patients undergoing primary angioplasty
There are experimental studies suggesting that metformin admin before and during ischemia and reperfusion could help to preserve left ventricular function regardless of glycometabolic state.In observational studies, the concomitant use of metformin is associated with a lower peak CK MB and troponin.380 nondiabetic patients undergoing primary angioplasty for acute coronary syndrome study with ST segment...
STAMPEDE Trial: Bariatric surgery was superior to optimal medical therapy to glycemic control in obese type 2diabetics
In the short term, bariatric surgery showed improvement in glycemic control of obese type 2 diabetics.This study evaluated the course at 3 years of 150 obese type 2 diabetic patients randomized to intensive medical therapy or intensive clinical treatment plus bariatric surgery. The primary endpoint was a glycosylated hemoglobin of 6% or less.The mean age...
ALECARDIO Trial: Aleglitazar associated with severe adverse events in diabetic patients with acute coronary syndrome
This randomized, double-blind, placebo-controlled, multicenter work evaluated the potential cardiovascular reduction risk and the long-term safety profile of Aleglitazar, compared with placebo in patients with type 2 diabetes experiencing an acute coronary syndrome. A total of 7226 patients were randomized at 12 weeks post-acute coronary event to receive Aleglitazar 150 ug or placebo. The study...
GRACE: Use of insulin glargine and fatty acids to reduce atherosclerosis progression.
Presentation Summary: There is a clear association between hyperglycemia and the development of atherosclerosis. The GRACE sub trial, (from ORIGIN study), evaluated the administration of omega-3 and insulin glargine and their benefits in reducing atherosclerosis progression. Conducted at 32 centers in 7 countries, this study included 1,092 individuals with hyperglycemia and increased risk of cardiovascular...
POSEIDON study: A prospective, randomized, single-center study comparing a sliding-scale hydration strategy for the prevention of contrast-induced nephropathy.
Background: Contrast-induced nephropathy has been the subject of many studies not only because of the morbidity associated with prolonged hospital stay, (with dialysis requirement in some cases), but also with an increase in mortality in these patients. The preventive strategy hydration with saline solution 0.9% NaCl is the choice. However, the infusion rate and total...
FREEDOM trial: CABG versus angioplasty treatment for diabetic patients with multivessel disease
The trial included 1,900 patients followed for at least 2 years, (mean 3.8 years), randomized 1:1 to pharmacological angioplasty stents, (sirolimus or paclitaxel at surgeon discretion), or CABG. We excluded acute coronary syndromes and left coronary trunk injury. The primary endpoint was death, myocardial infarction or stroke and the secondary main was the sum of...
THRIVE: Niacin/laropiprant extended release showed no significant cardiovascular benefit.
The THRIVE study, (also known as HPS2-THRIVE), was a multicenter clinical trial designed to test the hypothesis that the increase in HDL, (using ER niacin/laropiprant), could prevent vascular events in a high risk population already receiving statin standard therapy. Between April 2007 and July 2010 a total of 25,673 randomized patients in China, the UK...